martin-weiblen

Prof. Dr. Martin Weiblen, Managing Partner

Martin Weiblen is Managing Partner of HeidelbergCapital.

Prior to HeidelbergCapital Martin has worked in the metal industry and from 1980 he was a Corporate Executive in various Finance and Holding functions of Corange / Boehringer Mannheim, a then $4bn global Healthcare Group, in Germany, London/U.K. and Luxembourg. After the acquisition of the group by Roche, Basle/Switzerland, Martin established and led as MD a multi-billion Family Office in London/U.K. for almost 10 years, focussing on Global Asset Management and direct investments in various start-ups in Germany, Singapore and the U.S. He was also instrumental in the set-up of Venture Capital and Private Equity funds. Martin has been serving on several Advisory- and Supervisory Boards and is teaching as Professor for Finance und Strategic Management at Pforzheim University.

Martin Weiblen holds a Master’s Degree in Business Administration from the University of Erlangen-Nuremberg/Germany and received a PhD in Economics from the University of Mainz/Germany, where he also was MD of an independent Research Institute.

clemens-doppler

Dr. Clemens Doppler, Managing Partner

Clemens Doppler is Managing Partner of HeidelbergCapital.

Prior to HeidelbergCapital Clemens was a Partner at 3i and has worked in various markets and geographies. He specialises in life science and emerging technologies and managed more than 100 million USD for 3i. Clemens started his career in R&D and has held senior positions in business development. He worked at Boehringer Mannheim (now Roche) before he joined one of the first Swiss Biotech companies as executive, which was successfully sold in 1997 to MDS, Inc (former Phoenix International Life Science, Montreal & NJ .), a world leading Pharma services provider. Clemens currently serves on the board of 4SC, Accovion, MerLion, Sensovation and Vasopharm. Most recent exits include the IPO’s of 4SC and Santhera where he was also responsible for the preceding M&A transaction and the reversed take over of NASDAQ listed Cancervax by Micromet. Further key deals that he has been involved in include Brahms, EMBL Tech Fund, HBM, Human Optics, Pharmexx and Vasopharm and the merger of Combinature and Atheals with Singapore based MerLion Pharmaceuticals.

Clemens graduated from the Ruprecht-Karls-University of Heidelberg/Germany as a Master of Science in Biology and a Ph.D. in Molecular Biology. He has also worked as Research Associate at the German Cancer Research Centre in Heidelberg/Germany.

andre-deloch

André Deloch, Partner, Buyouts

André Deloch has been Partner to HeidelbergCapital since 2012.

André supports HeidelbergCapital in buyout transactions and banking. Andre has extensive experience in portfolio management of majority and minority positions for PE funds, especially in healthcare, industry and service. Prior to supporting HeidelbergCapital, Andre worked for more than 9 years as Director of 3i Germany in buyouts and was involved in the successful completion of buyout transactions worth more than €1.7bn. Andre is currently operationally responsible for repositioning and restructuring projects of Private Equity portfolio companies as Senior Advisor. Andre started his career as an international trainee at Volkswagen, where he conducted procurement projects for model launches in Germany, Spain and Mexico. After that he worked for the DZ Bank in Frankfurt in business and turn around consulting for companies of the credit and portfolio equity holdings.

André holds a degree in Industrial Engineering (production, financing and marketing) of the Technical University of Braunschweig.

florian-festner

Florian Festner, Investment Director

Florian Festner joined HeidelbergCapital in 2008.

During his studies he gained first international experience at renowned companies in Germany, Asia and the US. Florian started his private equity career with 3i in Zurich/Switzerland, where he was working on various Buyout, Growth Capital und Venture Capital projects. In 2006 he joined the Frankfurt based Growth Capital Team of 3i and focussed on minority investments in ’Mittelstand’ companies. Florian was also involved in the management of portfolio companies and was an observer in the board of these companies.

Florian studied Business at the University of Erlangen-Nuremberg/Germany and finished his Master’s degree at the Catholic University of Eichstätt-Ingolstadt/Germany. In addition he holds a Master’s degree in business law from the University of Sydney/Australia.

Markus-Reinhard

Markus Reinhard, Director Finance

Markus Reinhard unterstützt HeidelbergCapital seit Ende 2016 in sämtlichen kaufmännischen Angelegenheiten. Er bringt nicht nur eine langjährige Erfahrung aus multinationalen Pharmakonzernen (Knoll, Abbott, GSK) mit, sondern hat auch in führender Funktion den kaufmännischen Bereich eines Biotechnologie Startups (Cellzome) aufgebaut, welches später erfolgreich an einen der weltweit größten Pharmakonzern verkauft werden konnte. Markus war im Laufe seines Berufsweges maßgeblich an diversen Integrationsprojekten beteiligt und konnte in einem internationalen Umfeld eine breite Erfahrung in verschiedenen kaufmännischen Bereichen gewinnen.

Markus schloss sein Studium der BWL mit Schwerpunkten Finanz- und Rechnungswesen und Controlling an der Fachhochschule in Ludwigshafen ab.

 

diane-lechner

Diane Lechner, Assistant

Diane M. Lechner joined HeidelbergCapital as Office Assistant in April 2009.

Prior to HeidelbergCapital she worked as personal assistant at Abbey Life Assurance in England, followed by several years in a similar position at the Berlitz Language School in Heidelberg.